Category: WFN1 Contributors

123421520 / 2150 POSTS
By Steven Ralston, CFA OTC:BLSTF | ASX:BSX READ THE FULL BLSTF RESEARCH REPORT Blackstone Minerals (OTC:BLSTF) (ASX:BSX) is advancing both upstream and downstream nickel projects in northern Vietnam. The upstream Ta Khoa Project is developing a serie ...
By John Vandermosten, CFA EPA:ALQGC READ THE FULL ALQGC RESEARCH REPORT QUORUM Study Results Announcement Quantum Genomics S.A. (EPA:ALQGC) reported topline results for the QUORUM study which were presented at the European Society of Cardiology (ESC ...
By John Vandermosten, CFA NASDAQ:HTBX READ THE FULL HTBX RESEARCH REPORT Business Update Conference Call Heat Biologics, Inc. (NASDAQ:HTBX) hosted a business update conference call on September 2, 2021 to discuss the status of active programs, objec ...
Following up with prospects is crucial to closing. There are plenty of things that prospects like to hear, and can help make your follow-up more effective. I think we both know the almost impossibility of making a sale on the very first contac ...
By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT Business Update PDUFA Date for BXCL501 of January 5, 2022; MAA Submission Expected 2H21 In May 2021, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) announced that the New Drug Application ( ...
By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT Document Security Systems (NYSE:DSS) has evolved into a multi-industry business growing through opportunistic acquisitions. Its roots lie in packaging and document printing. It has a new dir ...
By John Vandermosten, CFA NASDAQ:TLSA | LSE:TILS READ THE FULL TLSA RESEARCH REPORT On September 2nd, Tiziana Life Sciences PLC (NASDAQ:TLSA) (LSE:TILS) announced an exclusive licensing agreement with Precision BioSciences (NASDAQ:DTIL) for the explo ...
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Nearing End of Phase 2 Analysis for EB05 Phase 2/3 Trial in COVID-19 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting a Phase 2/3 clinical trial of EB05 in pa ...
By David Bautz, PhD OTC:APLIF | TSX:APLI.TO READ THE FULL RESEARCH REPORT Business Update Awaiting Data Readout of PRESECO Trial in COVID-19 In May 2021, Appili Therapeutics, Inc. (OTC:APLIF) (TSX:APLI.TO) announced that the independent Data Safety M ...
By Lisa Thompson OTC:PKKFF READ THE FULL PKKFF RESEARCH REPORT Peak Fintech (OTC:PKKFF) blew away our revenue estimate of $25 million coming in with a $30.6 million quarter, which was growth of 322% compared with last year. Taking out the bank intere ...
123421520 / 2150 POSTS